Doctor of Philosophy in Experimental Medicine (PhD)
Regulation of gene expression by phosphorylation of transcription factors.
Investigation of protein kinase signalling networks in diverse experimental model systems, including growth factor-treated human cancer cell lines and meiotic maturation of sea star and frog oocytes. Investigations of protein kinase signalling networks in biopsied human tissues from patients with cancer, neurological disorders and diabetes. Development of microarray technology for monitoring protein expression, covalent modification, protein-protein interactions and protein-drug interactions. Meta-analysis of high-throughput proteomics data for development of algorithms for predicting the architecture and operations of cell signalling systems. As a hybrid academic-industrial laboratory, the research seeks to support both basic and applied research goals.
Applicants should have a strong background in biochemistry at the undergraduate level in advance third and fourth years courses, and experience in research laboratories that have used cell culture, protein analysis, enzyme assays and immunology-base techniques such as Western blotting. Applicants should have a minimum 87.5% average in undergraduate and any graduate courses, and/or strong evidence of research ability supported by authorship in peer-reviewed, scientific publications.
G+PS regularly provides virtual sessions that focus on admission requirements and procedures and tips how to improve your application.
These videos contain some general advice from faculty across UBC on finding and reaching out to a potential thesis supervisor.
Dissertations completed in 2010 or later are listed below. Please note that there is a 6-12 month delay to add the latest dissertations.
The antibody microarray platform has emerged as an innovative and economical tool for ultra- sensitive, semi-quantitative interrogation of protein expression, post-translational modifications such as phosphorylation, and interactions with other proteins and small molecules. While this technology possesses unique strengths such as compatibility to directly assay biofluids as well as tissue and cell specimens without enrichment, the interpretation of antibody microarray findings have been plagued by the biological complexity of protein-protein interactions, poor sample handling, and inadequately characterized antibodies. Further refinement of the antibody microarray platform can identify proteomic cell signalling events in a targeted approach that is still high throughput and relatively accurate. To this end, this thesis describes recent innovations in the design, production and characterization of over 600 phosphosite-specific antibodies used in printing antibody microarrays, as well as refinements in sample preparation and detection systems to yield significant improvements in data quality. The resulting KAM-1325 antibody microarray was then used to investigate the associated similarities and differences between epidermal growth factor and insulin-mediated metabolic signal transduction pathways, as well as the effects of inhibition of protein-tyrosine phosphatases and protein synthesis. Taken together, along with over 250 different experiments performed with the same array with samples from diversified model systems and treatments, I used correlative analysis to propose physiological protein-protein relationships with a focus on kinase-substrate connections. I have also developed maps of common cell signalling networks of known and proposed novel protein connections relating to the targets that are tracked with antibodies on the KAM-1325 antibody microarray. To validate some of these connections, invitro kinase assays were performed. These experiments involved direct incubation of cell lysates with purified recombinant protein kinases and surveillance of enhanced phosphorylation of substrate proteins with the antibody microarray. The continued elucidation of cell signalling systems will help discern between healthy and pathological states of cells and organisms, so that future therapies that utilize these signalling pathways to restore homeostasis and wellbeing can be developed.
The eukaryotic protein kinases (ePKs) constitute one of the largest families of enzymes encoded by eukaryotic genomes. They regulate all cellular processes by transducing inter- and intracellular signals via the phosphorylation of specific protein substrates. The primary sequences of ePK catalytic domains are highly conserved, indicating a common ancestry. They all share a conserved catalytic core for their phosphotransferase function and often a common activation mechanism by phosphorylation of a variable segment known as the activation T-loop. Starting from a manually aligned and annotated map of 492 typical human protein kinase domains, I first explored the origin of ePKs using a modified BLAST method in various species. Comparisons of primary, secondary and tertiary structures supported the hypothesis that protein kinases and choline kinases evolved from an ancient aminoacyl-tRNA ligase. Secondly, I studied the functional roles of two extremely conserved phosphosites that exist ubiquitously in the activation T-loops of most protein-serine/threonine kinases. The extensively examined extracellular signal-regulated kinases (ERKs) 1/2 from the mitogen-activated protein kinase family were used as a model in this study. I discovered that both Thr-207 and Tyr-210 from human ERK1 were essential for regulation of its phosphotransferase activity. Autophosphorylation of Thr-207 played an inhibitory role to control ERK1 activity after the initial phosphorylation and activation by MEK1. This may serve as a general mechanism for kinase autoinhibition. I also examined the substrate specificities of more than 200 human protein kinases with peptide microarrays populated with semi-optimal substrate sequences. The resultant data were used to expand the training datasets for development of next generation protein kinase substrate predictive algorithms. Additionally, I describe a novel method to produce a more unbiased polyclonal generic phosphotyrosine antibody than the monoclonal antibodies that are commonly used to enrich and track tyrosine-phosphorylated proteins. The tools and knowledge resulting from this research should enable improvements in the characterization of protein kinases and establishing their linkages to a variety of human diseases for the development of better diagnostic tests and therapeutic drugs. This work also provides basic insights into the evolution of life and the specific architecture of protein kinase-based signalling systems.
Defects in cell signalling networks are linked to over 400 human diseases. My thesis research aimed to model these networks in more detail to facilitate understanding of their architecture and operations under normal and pathological conditions. The various protein levels in diverse normal human cell and tissue types were inferred from their mRNA expressions, and their up/down-regulation was also investigated in about 300 human cancer cell lines and 50 types of human cancers. This was based on meta-analyses of gene microarray measurements deposited in the USA National Center for Biotechnology Information's Gene Expression Omnibus database. I identified proteins that were commonly or uniquely expressed in normal and cancerous human cells and tissues. The co-expression patterns of proteins were used to predict potential interactions, but there was not a strong correlation between high co-expression and actual direct protein-protein interactions documented in the scientific literature. With respect to the post-translational regulation of proteins, my research efforts primarily targeted protein phosphorylation, which is the most predominant type of reversible covalent modification of proteins. Complex protein phosphorylation networks emerge through the interplay of protein kinases, protein phosphatases, phosphorylation site-dependent binding proteins, and their phosphoprotein substrates. I modelled the interactions of protein kinases with substrate proteins and inhibitory compounds. Nearly a million human phosphosites were predicted, and each of these was tested in silico as substrates for 500 human protein kinases. The interactions of over 550 known protein kinase inhibitory drugs with the 500 protein kinases were also tested. These predicted interactions were compared with empirical data from other on-line protein-protein and protein-drug interaction databases. The human phosphosites were also analysed with respect to their protein conservation in over 20 other diverse species, and it was found that threonine phosphosites in protein kinases that were activatory were particularly well conserved in evolution. Finally, probabilistic graphical models were developed to model the most probable structure of substrate phosphosites for specific protein kinases. The discussed probabilistic graphical model, gave more theory justifications for the protein-protein interaction modelling that was presented in the earlier parts of the thesis.